325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells

• Joshua Brody,
• Stephen Willingham,
• Richard Miller,
• Thomas Marron,
• Gerard Criner,
• Mehrdad Mobasher,
• Craig Hill,
• Shenshen Hu,
• Suresh Mahabhashyam

Affiliations

Joshua Brody

3Icahn School of Medicine at Mount Sinai, New York, NY, USA

Stephen Willingham

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA

Richard Miller

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA

Thomas Marron

3Icahn School of Medicine at Mount Sinai, New York, NY, USA

Gerard Criner

1Temple University Hospital, Philadelphia, USA

Mehrdad Mobasher

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA

Craig Hill

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA

Shenshen Hu

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA

Suresh Mahabhashyam

2Corvus Pharmaceuticals Inc, Burlingame, CA, USA